1. Search Result
Search Result
Results for "

TIM

" in MedChemExpress (MCE) Product Catalog:

17

Inhibitors & Agonists

11

Inhibitory Antibodies

30

Recombinant Proteins

6

Antibodies

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-155175

    Tim3 Cancer
    TIM-3-IN-2 (Compound A-41) is a Tim3 inhibitor (KD: 0.61 μM). TIM-3-IN-2 blocks TIM-3 interactions with PtdSer, CEACAM1, and Gal-9. TIM-3-IN-2 inhibits the immunosuppressive function of TIM-3. TIM-3-IN-2 reverses the TIM-3-mediated blockade of the production of proinflammatory cytokines, and maximizes the T-cell antitumor activity against AML cell lines .
    TIM-3-IN-2
  • HY-139738

    Tim3 Cancer
    TIM-3-IN-1 (Compound 38) is a TIM-3 inhibitor that can be used for the research of cancer .
    TIM-3-IN-1
  • HY-148757

    CaMK Metabolic Disease
    TIM-063 is a selective and cell-permeable CaMKK inhibitor, ATP competitive inhibitor, can directly target the catalytic domain of CaMKK, with the Ki values of 0.35 μM and 0.2 μM for CaMKKα and CaMKKβ, respectively, the IC50 values are 0.63 μM and 0.96 μM, respectively .
    TIM-063
  • HY-P990004

    Tim3 Cancer
    Anti-Mouse TIM-3 Antibody (B8.2C12) is an anti-mouse TIM-3 antibody inhibitor. Anti-Mouse TIM-3 Antibody (B8.2C12) is a rat IgG1κ subtype antibody .
    Anti-Mouse TIM-3 Antibody (B8.2C12)
  • HY-P99044
    Sabatolimab
    1 Publications Verification

    MBG453

    Tim3 Inflammation/Immunology Cancer
    Sabatolimab (MBG453) is a high-affinity, humanized, IgG4 (S228P) antibody targeting TIM-3, an inhibitory receptor that regulates adaptive and innate immune responses. Sabatolimab is a potential immunosuppression agent that can target TIM-3 on immune and myeloid cells .
    Sabatolimab
  • HY-P99962

    BGB-A425

    Mucin Cancer
    Surzebiclimab (BGB-A425) is a humanized IgG1-variant monoclonal antibody against T-cell immunoglobulin and mucin-domain containing-3 (TIM-3). Surzebiclimab binds to the extracellular domain of human Tim-3 with high affinity (KD=0.36 nM) and specificity. Surzebiclimab can be used in research of cancer .
    Surzebiclimab
  • HY-162388

    AAK1 Neurological Disease
    TIM-098a is a selective AAK1 inhibitor with an IC50 of 0.24 µM. TIM-098a has no inhibitory activity against CaMKK isoforms. TIM-098a inhibits AAK1-regulated endocytosis by suppressing AAK1 kinase activity .
    TIM-098a
  • HY-E70075

    GDH-TIM; GDH-TPI

    Transketolase Metabolic Disease
    α-Glycerophosphate Dehydrogenase-Triosephosphate (GDH-TIM) is an enzyme mixture composed of glycerol phosphate dehydrogenase (GDH) and triphosphate isomerase (TIM). α-Glycerophosphate Dehydrogenase-Triosephosphate can be used to determine the activity of transketolase (TK) in hemolytic substances of red blood cells to evaluate vitamin B deficiency .
    α-Glycerophosphate Dehydrogenase-Triosephosphate
  • HY-P990152

    Akt ERK Others
    Anti-Mouse TIM-4 Antibody (RMT4-54) is a rat-derived IgG2a, κ type antibody inhibitor, targeting to mouse TIM-4.
    Anti-Mouse TIM-4 Antibody (RMT4-54)
  • HY-P990820

    Mitochondrial Metabolism Others
    Anti-Mouse TIM-4 Antibody (RMT4-53) is a kind of rat IgG2b kappa in vivo mouse antibody, targeting to TIM-4. The recommend isotype control of Anti-Mouse TIM-4 Antibody (RMT4-53): Rat IgG2b kappa, Isotype Control (HY-P990682).
    Anti-Mouse TIM-4 Antibody (RMT4-53)
  • HY-159884

    Tim3 TNF Receptor IFNAR Cancer
    MG-T-19 is an effective TIM-3 inhibitor that can suppress the interaction of TIM-3 with PtdSer, CEACAM1, and Gal-9. MG-T-19 can increase the production of tumor necrosis factor-α (TNF-α) and interferon-γ (IFN-γ) in peripheral blood mononuclear cells (PBMCs) from healthy donors, and enhance the ability of PBMCs to inhibit the proliferation of Kasumi-1 cells (an acute myelogenous leukemia cell line) .
    MG-T-19
  • HY-P99827

    TSR-022; GSK4069889

    Tim3 Cancer
    Cobolimab (TSR-022) is an anti-TIM-3 monoclonal antibody. Cobolimab mediates the internalization of TIM3 with an IC50 value of 0.4464 nM. Cobolimab has potential application in solid tumors and non-small cell lung cancer (NSCLC) .
    Cobolimab
  • HY-163028

    Tim3 Cancer
    ML-T7 is a potent Tim-3 inhibitor. ML-T7 blocks Tim-3 interactions with PtdSer and CEACAM1. ML-T7 not only enhances the antitumor activity of adoptive transfer therapy with cytotoxic T lymphocytes (CTLs) and CAR T cells but also increases the effector function of T cell. ML-T7 promotes NK cells’ killing activity against tumor cells and DC antigen-presenting capacity. ML-T7 directly exerts antitumor efficacy in preclinical tumor models either alone or in combination with Nivolumab (HY-P9903A). ML-T7 can be used for tumor immunotherapy research .
    ML-T7
  • HY-149916

    Adenosine Receptor Cancer
    A2AR-antagonist-1 (compound 38) is an orally active adenosine A2A receptor (A2AR) antagonist (IC50=29 nM). A2AR-antagonist-1 exhibits anti-tumor activity and mouse liver microsomal metabolic stability (t1/2=86.1 min). A2AR-antagonist-1 is also a T cells activator, via inhibiting immunosuppressive molecules (LAG-3 and TIM-3) and enhancing effector molecules (GZMB, IFNG, and IL-2) .
    A2AR-antagonist-1
  • HY-144088

    HPK1-IN-22

    MAP4K Inflammation/Immunology Cancer
    ZYF0033 is effective in inhibiting hematopoietic progenitor cells HPK1, basically inhibiting MBP protein oxidation IC50 10 nM . ZYF0033 promotes anti-cancer immune response, lowers SLP76 (acid 376) oxidation. ZYF0033 Suppression 4T-1 Small mouse model with the same underlying cause, medium bulge growth length expansion DC, NK 细细和 CD107a + CD8 + T Cells, PD-1 +CD8 + T Cells, TIM-3 +CD8 + T Cells LAG3< sup>+CD8 + T Cellular immersion decreases.
    ZYF0033
  • HY-115467
    MitoBloCK-10
    2 Publications Verification

    HSP Metabolic Disease
    MitoBloCK-10 (MB-10) is the first small molecule modulator to attenuate protein-associated motor (PAM) complex activity. MitoBloCK-10 (MB-10) inhibits Tim44 (C-terminal domain) binding to the precursor and to Hsp70 .
    MitoBloCK-10
  • HY-145240

    Eukaryotic Initiation Factor (eIF) Infection Cancer
    eIF4E-IN-1 is a potent inhibitor of eIF4E. eIF4E-IN-1 inhibits immunosuppression components such as immune checkpoint proteins PD-1, PD-L1, LAG3, TIM3, and/or IDO, in order to inhibit or release immune suppression in certain diseases, such as cancer and infectious disease (extracted from patent WO2021003194A1, compound Y) .
    eIF4E-IN-1

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: